Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SETD1B | Q9UPS6 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959968 | 0.91 | FBP1 (0.56) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4570017 | 0.85 | FBP1 (0.57) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4570117 | 0.83 | FBP1 (0.56) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4570506 | 0.80 | FBP1 (0.56) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4566925 | 0.78 | FBP1 (0.51) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL958486 | 0.77 | FBP1 (0.53) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4570288 | 0.72 | FBP1 (0.46) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL957160 | 0.72 | FBP1 (0.80) | FBP1 | |
| SCHEMBL962214 | 0.71 | FBP1 (0.47) | FBP1SMN1; SMN2NPC1LMNAPKM | |
| SCHEMBL4569970 | 0.71 | FBP1 (0.57) | FBP1SMN1; SMN2NPC1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868030-B2 | FBPase inhibitors for diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-2032548-A1 | THIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | HOFFMANN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | FBP1, PFKFB1, PFKFB3 | FBP1 1/4885SMN1; SMN2 3284/4885NPC1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.